Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
September 8, 2022: Biosegen AB (“Biosergen” or the “Company”) today announced that the phase I study in Australia will now move into the MAD part of the study after testing 4 cohorts in the SAD part of the study. It was expected that infusion reactions would appear in the healthy volunteers and limit further dose escalations. There were no impact at all on the kidney and liver parameters which is a major achievement for the development of BSG005.The Safety Review Committee for this study has reviewed all the available safety and PK data and concluded that the dose level achieved did not